菜单

CRO Services

Drug Development Expertise Empowering Research Services for Biologics

 

 

Standard bioassays often fall short when evaluating T cell engagers due to their diverse mechanisms of actions (MOAs) and functional complexity. To generate meaningful preclinical data, context-specific in vitro models are essential.

 

In this webinar, we will explore the strategic application of tailored bioassays for T cell engagers (TCEs) in oncology. Through real-world case studies, we will demonstrate how rational assay design, such as T cell activation, redirected killing, cytokine release, and target-specific inhibition, can support robust assessment of drug potency, specificity, and MOAs.

 

Key Takeaways:

 

  • Proven strategies for assay design, optimization, and biological interpretation in preclinical development
  • How in vitro models like bispecific format evaluation can bridge discovery and translational relevance
  • Practical approaches for transforming complex bioassay data into actionable insights to guide drug development

 

 

Webinar Details

 

Date: Tuesday, June 24, 2025

Time: 8:00 AM PT | 11:00 AM ET | 4:00 PM BST

 

 

Speaker:

 

 

 

Rachel Wang, Ph.D.

Associate Director, CRO Services

 

Dr. Rachel Wang is a seasoned immunologist with over 15 years of experience in therapeutic antibody development, specializing in immuno-oncology, autoimmune, and inflammatory diseases. She earned her Ph.D. in Molecular and Cellular Immunology from City of Hope and has led discovery and translational programs at multiple Bay Area biotech companies. At WuXi Biologics, she serves as a subject matter expert, advising global clients on in vitro assay design for T cell engagers and immune-modulating biologics. Her expertise includes flow cytometry, cytokine analysis, and complex cell-based functional assays.

Enter your information to watch the recording

 

Have specific questions about in vitro TCE assays?

Reach out to our experts!